胸腺五肽联合无创通气治疗稳定期慢阻肺合并2型呼吸衰竭疗效

Therapeutic effect of thymopentin combined with noninvasive ventilation on stable chronic obstructive pulmonary disease with type 2 respiratory failure

目的:探讨对胸腺五肽联合无创通气治疗稳定期慢阻肺合并2型呼吸衰竭疗效。方法:前瞻性纳入收集2018年4月20日~9月20日,处于稳定期慢性阻塞性肺病伴2型呼吸衰竭68例,随机分为治疗组36例和对照组32例。两组均用无创呼吸机治疗;治疗组同时利用胸腺五肽治疗。观察期为半年,观察血气分析(PaO2、PaCO2、SO2)、CRP、CD4和CD8细胞计数、CD4/CD8的比值;肺功能参数:FVC、FEV1、FEV1/FVC;急性发作频率、住院频率等指标。结果:与治疗前对比,两组pH值、PO2、PCO2、SaO2(%)、FEV1(L)、FEV1/FVC均有明显的改善,差异有统计学意义﹙P<0.05﹚;治疗组的pH值、PCO2、FEV1(L)、FEV1/FVC较对照组改善明显,差异有统计学意义(P<0.05);慢阻肺合并2型呼吸衰竭治疗前后CD4、CD4/CD8有明显的升高,CD8、CRP明显降低,治疗组较对照组改善明显,差异有统计学意义(P<0.05);两组慢阻肺合并2型呼吸衰竭治疗前后急性发作频率、住院频率对比,治疗组较对照组明显降低,差异有统计学意义(P<0.05)。结论:胸腺五肽联合无创通气治疗稳定期慢阻肺合并2型呼吸衰竭临床疗效良好。

Objective:To investigate the efficacy of thymopentin combined with non-invasive ventilation in the treatment of stable chronic obstructive pulmonary disease with type 2 respiratory failure. Methods:A total of 68 patients with chronic obstructive pulmonary disease(COPD) and type 2 respiratory failure who were treated from April 20, 2018 to September 20, 2018 were randomly divided into treatment group(36 cases)and control group(32 cases). Randomly divided into treatment group and control group, both groups were treated with non-invasive ventilator;the treatment group was treated with thymopentin at the same time. The observation period of each patient was half a year, and then the observation included: blood gas analysis(PaO2, PaCO2, SO2), CRP, CD4 and CD8 cell count, CD4/CD8 ratio;lung function parameters: FVC, FEV1, FEV1/FVC;acute attack frequency, hospitalization frequency and other indicators.Results:Compared with before treatment, the PH value, PO2, PCO2, SaO2(%), FEV1(L), FEV1/FVC of the two groups were significantly improved(P<0.05), while the PH value, PCO2, FEV1(L), FEV1/FVC of the treatment group were significantly improved compared with the control group, the difference was significant(P <0.05);COPD combined with type 2 expiration;CD4, CD4/CD8 increased significantly and CD8 and CRP decreased significantly before and after inhalation failure treatment, while the treatment group improved significantly compared with the control group(P<0.05). The acute attack frequency and hospitalization frequency of COPD with type 2 respiratory failure in the two groups before and after treatment were compared, the treatment group was significantly lower than the control group, the difference was significant(P<0.05). Statistical significance(P<0.05). Conclusion:Thymopentin combined with noninvasive ventilation is effective in the treatment of stable COPD with type 2 respiratory failure.